The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins

Author(s): Ludwig Christian G. Hinske, Florian Weis, Jens Heyn, Patricia Hinske, Andres Beiras- Fernandez

Journal Name: Recent Patents on Anti-Infective Drug Discovery
Continued as Recent Advances in Anti-Infective Drug Discovery

Volume 7 , Issue 1 , 2012

Become EABM
Become Reviewer
Call for Editor


Fungal infections are becoming an increasing menace in the hospital care setting. Among them, non-albicans Candida species have gained significant attention. Especially in the ICU setting, therapeutic options are limited in many cases by the side-effects of conventional antifungal therapy. Echinocandins are a relatively new class of antifungal agents that promise good effectiveness against Candida and Aspergillus species. Due to their underlying mechanisms of action, they yield good tolerability and few limitations of usage. In the current manuscript we describe the patents of two recently approved echinocandins, micafungin (US approved 2005) and anidulafungin (2006) and provide an overview of the mechanisms, clinical effectiveness and safety of antifungal therapy with these agents.

Keywords: anidulafungin, aspergillosis, candidemia, candidiasis, echinocandins, micafungin, fluconazole, patent, Caspofungin

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 01 May, 2012
Page: [1 - 7]
Pages: 7
DOI: 10.2174/157489112799829747

Article Metrics

PDF: 20